Search
Spiramycin
go.drugbank.com/drugs/DB06145ApprovedInvestigationalWithdrawnSpiramycin is a 16-membered ring macrolide discovered in 1952 as a product of Streptomyces ambofaciens that has been available in oral formulations since 1955, and parenteral formulations since 1987.
Cilansetron
go.drugbank.com/drugs/DB04885ExperimentalCilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Glembatumumab vedotin
go.drugbank.com/drugs/DB05996InvestigationalA conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
NE-180
go.drugbank.com/drugs/DB05619ExperimentalNE-180 was under investigation in a clinical trial conducted in the European Union.
Quinacrine
go.drugbank.com/drugs/DB01103InvestigationalAn acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. … It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
Felypressin
go.drugbank.com/drugs/DB00093InvestigationalIt is a non-catecholamine vasoconstrictor used in local anaesthetic injections for dental use, and is an ingredient of preparations that have been used for treatment of pain and inflammation of the mouth … A synthetic nonapeptide comprising cysteinyl, phenylalanyl, phenylalanyl, glutaminyl, asparaginyl, cysteinyl, prolyl, lysyl, and glycinamide residues in sequence, with a disulfide bridge joining the two
Vanillyl butyl ether
go.drugbank.com/drugs/DB11299ApprovedVanillyl butyl ether is an ether of monohydroxybenzoic acid. It is added to food products as a flavoring agent. … It is also present in cosmetics and personal care products as a fragrance ingredient, oral care agent, hair conditioning agent, and warming or cooling agent.
Amubarvimab
go.drugbank.com/drugs/DB16493InvestigationalAmubarvimab (BRII-196) was under investigation in clinical trials (NCT04691180 and NCT04787211) to treat COVID-19, focusing on its safety, tolerability, and efficacy.
Bacillus calmette-guerin substrain connaught live antigen
go.drugbank.com/drugs/DB10804ApprovedInvestigationalWithdrawnBacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary
Vimseltinib
go.drugbank.com/drugs/DB17520ApprovedInvestigationalA265035] It is intended to provide a safer alternative to [pexidartinib], a previously approved CSF1R inhibitor associated with significant liver toxicity - the greater selectivity of vimseltinib results in … [L52230,A265035] Vimseltinib - under the brand name Romvimza - was approved by the FDA in February 2025 for the treatment of tenosynovial giant cell tumours for which surgical resection is not appropriate